BiomX Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, effecting a one-for-ten reverse stock split of its common stock. This action became effective at 12:01 a.m., Eastern Time, on September 9, 2026, following approval by stockholders at a special meeting held on August 25, 2026. The amendment also reduced the number of authorized shares from 750,000,000 to 150,000,000. Trading in the common stock on a split-adjusted basis commenced with the market open on September 9, 2026, under CUSIP number 09090D 608, with fractional shares rounded up to the nearest whole share. Additionally, the company filed a separate amendment to change its name from BiomX Inc. to Tessera Defense and Homeland Security Inc., effective September 11, 2026, accompanied by a ticker symbol change to HLSQ. The company operates in the biotechnology sector.

BiomX Inc. announced a one-for-ten reverse stock split of its common stock, approved by shareholders on August 25, 2026. The Board fixed the ratio at 1-for-10 and set the effective date for September 9, 2026, when trading will resume on a split-adjusted basis on NYSE American. This action reduces authorized shares from 750 million to 150 million and outstanding shares from approximately 27.3 million to 2.7 million. Fractional shares are rounded up to whole shares at the record holder level, with no cash paid for fractions. Proportionate adjustments apply to warrants and convertible instruments. BiomX Inc. operates in the biotechnology industry, developing microbiome-based therapies.

BiomX Inc. announced a one-for-ten (1-for-10) reverse stock split of its common stock, effective September 9, 2026. The action was approved by stockholders on August 25, 2026, and finalized by the Board of Directors on August 28, 2026. This corporate action reduces authorized shares from 750 million to 150 million and decreases outstanding shares from approximately 26.7 million to 2.7 million. Fractional shares will be rounded up to the next whole share, and proportional adjustments apply to warrants and equity awards. BiomX Inc. operates in the biotechnology industry, focusing on developing microbiome-based therapies for inflammatory bowel disease.

On August 5, 2026, BiomX Inc. entered into a Share Purchase and Option Agreement to acquire 10% of M.E.A. Testing Systems Ltd. (MEA) for $50,000 cash and the issuance of 1,300,000 restricted common shares. The transaction includes an exclusive license to MEA's technology and an option to purchase Motomova Inc.'s remaining ~78.9% stake in MEA by June 30, 2028, with exercise price based on 2x net revenue or 4x EBITDA for fiscal year 2027. Closing is contingent upon NYSE American listing approval and execution of the license agreement. BiomX Inc. operates in the biotechnology industry, focusing on phage therapy solutions.

BiomX Inc. entered into Amendment No. 1 and Waiver to a $1,250,000 promissory note issued to Water IO Ltd. as part of the consideration for its April 2026 acquisition of ZorroNet Ltd. The amendment extends the note's maturity from July 10, 2026, to November 1, 2026, and waives prior defaults. BiomX will pay $250,000 of principal within two business days, followed by four equal monthly installments of $250,000. In exchange for the waiver and extension, the company agreed to issue 800,000 restricted shares of common stock to Water IO, subject to NYSE American listing clearance and corporate approvals, with a longstop date of August 31, 2026, after which payment converts to cash. This transaction involves a related party, as an independent BiomX board member also serves on Water IO's board. BiomX Inc. operates in the biotechnology industry, developing microbiome-based therapeutics.